

## Listing Rule 6.22.2 Adjustment to Option Exercise Prices

**Microba Life Sciences Limited (ASX:MAP)** ("**Microba**" or "**the Company**") advises it has options on issue which, under Listing Rule 6.22.2 and their terms and conditions, require their exercise price to be adjusted as a consequence of the Non-Renounceable Entitlement Offer that closed on 16 November 2023 (**Entitlement Offer**).

Listing Rule 6.22 confers on an option the right to a change to its exercise price if there is a pro-rata issue (except a bonus issue). The reduction to the exercise price to be applied is outlined in Listing Rule 6.22.2.

As a result of the recent Entitlement Offer, applying the formula in Listing Rule 6.22.2 requires a reduction in the exercise price of issued options of \$0.0118 per option.

In accordance with Listing Rule 3.11.2, Microba advises that, effective from 5 December 2023, the exercise price of the following options will be amended in accordance with their terms and conditions and the Listing Rules:

Details	Number of Options	Expiry Date	Original Exercise Price	Amended Exercise Price
Unlisted options	22,863,168	02/06/2024	\$0.3300	\$0.3182
Unlisted options	5,566,666	24/11/2024	\$0.3000	\$0.2882
Unlisted options	400,000	24/11/2024	\$0.2550	\$0.2432
Unlisted options	1,200,000	29/04/2025	\$0.6750	\$0.6632
Unlisted options	2,150,000	04/04/2026	\$0.3360	\$0.3242
Unlisted options	1,166,666	22/04/2026	\$0.3360	\$0.3242
Unlisted options	6,605,000	28/07/2027	\$0.4650	\$0.4532
Unlisted options	4,000,000	28/07/2027	\$0.6500	\$0.6382

*This announcement has been authorised for release by the Chair and CEO.*

For further information, please contact:

**Dr Luke Reid**  
Chief Executive Officer  
E: [Luke.Reid@microba.com](mailto:Luke.Reid@microba.com)

**Investor / Media Relations**  
E: [investor@microba.com](mailto:investor@microba.com)  
W: <https://ir.microba.com/>  
[Join our Investor Mailing List](#)

**About Microba Life Sciences Limited**

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

**For more information visit: [www.microba.com](http://www.microba.com)**

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.